Plasma Fatty Acid Composition in Continuous Ambulatory Peritoneal Dialysis Patients: An Increased Omega-6/Omega-3 Ratio and Deficiency of Essential Fatty Acids

Yerlikaya, Fatma Hümeyra; Mehmetoğlu, İdris; Kurban, Sevil; Tonbul, Zeki

doi:10.3109/0886022x.2011.601831

Cited by 16 publications

(9 citation statements)

References 15 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with a number of previous studies (for review see Khor et al ()), we detected decreased RBC EPA (C20:5 n‐3) levels in our CKD patients, compared to the control subjects. These changes were paralleled by decreased RBC C18:3 n‐6 and C20:3 n‐6 levels and decreased plasma levels of C18:2 n‐6, C20:3 n‐6, C20:4 n‐6, C20:5 n‐3, and C22:5 n‐6, which is similar to previous findings (Dasgupta, Kenny, & Ahmad, ; Dessi et al, ; Friedman, Moe, Perkins, Li, & Watkins, ; Friedman et al, ; Gomez Dumm, Giammona, Touceda, & Raimondi, ; Pazda, Stepnowski, Sledzinski, Chmielewski, & Mika, ; Peuchant et al, ; Sertoglu et al, ; Sikorska‐Wisniewska et al, ; Yerlikaya, Mehmetoglu, Kurban, & Tonbul, ), for review see Khor et al ()). However, the omega‐3 quotient did not vary between CKD patients and control subjects, which contrasts to numerous studies detecting a low omega‐3 index in CKD patients (for review see Khor et al ()).…”

Section: Discussionsupporting

confidence: 91%

Effects of hemodialysis on blood fatty acids

et al. 2020

View full text Add to dashboard Cite

Omega‐3 (n‐3) fatty acids have beneficial cardiovascular effects, perhaps also in chronic kidney disease (CKD) patients. A low omega‐3 index is an independent cardiovascular risk factor in end‐stage renal disease (ESRD) dialysis patients. However, the plasma measurements invariably ignore circulating blood cells, including the preponderant erythrocytes (RBCs). We measured fatty acids (HPLC‐MS lipidomics) in all components of the circulating blood, since RBC n‐3 fatty acid status has been linked to cardiovascular disease and mortality. We studied 15 healthy persons and 15 CKD patients undergoing regular hemodialysis treatments. While total fatty acid levels differed significantly in RBCs from healthy controls and CKD patients, the hemodialysis treatment had no effect on plasma or RBC fatty acid levels. No changes occurred in the percentage of eicosapentaenoic acid (C20:5 n‐3, EPA) and docosahexaenoic acid (C22:6 n‐3; DHA) (omega‐3 quotient) in RBC membrane fatty acids. Nonetheless, hemodialysis treatments increased plasma levels of various total fatty acids, namely C12:0, C14:0, C16:0, C20:2 n‐6, C20:4 n‐6, and C22:6 n‐3 (DHA), while plasma levels of free fatty acids were unchanged. These data suggest that despite significant changes in fatty acids signatures between healthy persons and CKD patients, hemodialysis does not alter RBC n‐3 fatty acid status, including the omega‐3 quotient. The dialysis treatment per se does not appear to be responsible for a lower omega‐3 index in CKD patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Effects of hemodialysis on blood fatty acids

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Yerlikaya et al. 20 measured fatty acid composition in plasma of patients on continuous ambulatory PD, and found ALA as well as other n-3 PUFA levels to be significantly lower, compared to the healthy control subjects. The present findings in our study may suggest that ALA follows a similar pattern to marine n-3 PUFA, with significantly lower levels in comparison to controls, and with a further decline during dialysis treatment.…”

Section: Discussionmentioning

confidence: 99%

Disorders of serum omega-3 fatty acid composition in dialyzed patients, and their associations with fat mass

et al. 2017

View full text Add to dashboard Cite

Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular mortality. Lipid disorders, a constant feature of CKD, might contribute to this state. The aim of this study was to evaluate n-3 polyunsaturated fatty acids (PUFA) composition in CKD patients treated with dialysis, in comparison to the general population and to assess possible associations between the n-3 PUFA profile and anthropometric variables. Thirty-three prevalent dialysis patients were studied and compared with an age- and sex-adjusted control group of 22 patients. Fatty acid composition in serum was analyzed by gas chromatography with a mass spectrometer detector (GC-MS) and anthropometric measures were assessed by bioimpedance spectroscopy. The fatty acid profile of dialyzed patients was characterized by a significantly lower percentage content of n-3 PUFA. For α-linolenic acid (ALA), it was 0.21 ± 0.09% in dialysis patients versus 0.33 ± 0.11% in the control group (p < .001). For eicosapentanoic acid (EPA), 0.59 ± 0.23% versus 1.15 ± 0.87% (p < .001), and for docosahexaenoic acid (DHA) 1.11 ± 0.50% versus 1.75 ± 0.87% (p < .001), respectively. The amount of n-3 PUFA decreased with time on dialysis and it correlated positively with body fat mass. For DHA, this correlation was r = .48 (p < .01) and for EPA r = .40 (p < .05). Patients with CKD have a relatively low content of n-3 PUFA which may contribute to their high cardiovascular risk. Patients with a higher content of body fat are characterized by a favorable fatty acid composition.

show abstract

“…PD is known to promote malnutrition and excessive loss of free amino acids, essential fatty acids [55], and albumin [56], leading to muscle wasting [57]. The downregulation of leptin mRNA in peritoneal tissues from both EPS and PD patients (Figure S2) may reflect malnourishment in chronic PD patients, as serum leptin levels fall during long-term fasting [58].…”

Section: Discussionmentioning

confidence: 99%

Transcriptional Patterns in Peritoneal Tissue of Encapsulating Peritoneal Sclerosis, a Complication of Chronic Peritoneal Dialysis

et al. 2013

View full text Add to dashboard Cite

Encapsulating peritoneal sclerosis (EPS) is a devastating complication of peritoneal dialysis (PD), characterized by marked inflammation and severe fibrosis of the peritoneum, and associated with high morbidity and mortality. EPS can occur years after termination of PD and, in severe cases, leads to intestinal obstruction and ileus requiring surgical intervention. Despite ongoing research, the pathogenesis of EPS remains unclear. We performed a global transcriptome analysis of peritoneal tissue specimens from EPS patients, PD patients without EPS, and uremic patients without history of PD or EPS (Uremic). Unsupervised and supervised bioinformatics analysis revealed distinct transcriptional patterns that discriminated these three clinical groups. The analysis identified a signature of 219 genes expressed differentially in EPS as compared to PD and Uremic groups. Canonical pathway analysis of differentially expressed genes showed enrichment in several pathways, including antigen presentation, dendritic cell maturation, B cell development, chemokine signaling and humoral and cellular immunity (P value<0.05). Further interactive network analysis depicted effects of EPS-associated genes on networks linked to inflammation, immunological response, and cell proliferation. Gene expression changes were confirmed by qRT-PCR for a subset of the differentially expressed genes. EPS patient tissues exhibited elevated expression of genes encoding sulfatase1, thrombospondin 1, fibronectin 1 and alpha smooth muscle actin, among many others, while in EPS and PD tissues mRNAs encoding leptin and retinol-binding protein 4 were markedly down-regulated, compared to Uremic group patients. Immunolocalization of Collagen 1 alpha 1 revealed that Col1a1 protein was predominantly expressed in the submesothelial compact zone of EPS patient peritoneal samples, whereas PD patient peritoneal samples exhibited homogenous Col1a1 staining throughout the tissue samples. The results are compatible with the hypothesis that encapsulating peritoneal sclerosis is a distinct pathological process from the simple peritoneal fibrosis that accompanies all PD treatment.

show abstract

Plasma Fatty Acid Composition in Continuous Ambulatory Peritoneal Dialysis Patients: An Increased Omega-6/Omega-3 Ratio and Deficiency of Essential Fatty Acids

Cited by 16 publications

References 15 publications

Effects of hemodialysis on blood fatty acids

Effects of hemodialysis on blood fatty acids

Disorders of serum omega-3 fatty acid composition in dialyzed patients, and their associations with fat mass

Transcriptional Patterns in Peritoneal Tissue of Encapsulating Peritoneal Sclerosis, a Complication of Chronic Peritoneal Dialysis

Contact Info

Product

Resources

About